Lubrizol Hikes Drug Product Manufacturing Capacity
Lubrizol has announced a $60 million investment in new product solutions, capacity expansion, and additional cGMP manufacturing to strengthen its excipients, polymers, drug formulation, and manufacturing, and medical device contract manufacturing capabilities at the company’s LifeSciences’ global facilities.
Commercial drug product manufacturing will be added at the company's Particle Sciences facility in Bethlehem, Pennsylvania, USA. The facility, which will accommodate sterile and non-sterile products, highly potent compounds, and organic solvent processing, will be adjacent to the existing development and clinical trial manufacturing site. The new space is expected to start operation in the fourth quarter of 2017.
The company also announced expansion of its global facilities for excipients, polymers, and contract manufacturing at multiple sites to increase in-house engineering capacity for medical and pharmaceutical applications. This includes new investments in design, manufacturing and sterilization technologies for the production of interventional catheters and long-term implantable devices.
